<DOC>
	<DOCNO>NCT02575781</DOCNO>
	<brief_summary>Primary Objectives : To determine maximum tolerate dose ( MTD ) SAR428926 administer single agent patient advance solid tumor . To evaluate anti-tumor response SAR428926 administer single agent patient advanced triple negative breast cancer ( TNBC ) positive protein target SAR428926 To assess preliminary anti-tumor response SAR428926 administer single agent patient advance solid tumor positive protein target SAR428926 Secondary Objectives : To determine overall safety profile SAR428926 single agent . To characterize pharmacokinetics ( PK ) profile SAR428926 metabolites . To identify recommended Phase 2 dose ( RP2D ) SAR428926 single agent . To evaluate immunogenicity SAR428926 . To assess tumor response duration tumor response treat patient . To evaluate benefit primary prophylaxis occurrence corneal ( keratopathy/keratitis ) toxicity ( Expansion cohort ) .</brief_summary>
	<brief_title>A Study SAR428926 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study duration individual patient include screen period inclusion 28 day , treatment period , end-of-treatment ( EOT ) visit around 30 day follow last administration SAR428926 , least one follow-up visit around 30 day EOT visit . The treatment period may continue disease progression , intolerable toxicity , investigator , Sponsor , patient decision discontinue therapy . Patients discontinue treatment reason progression disease follow every 3 month progression , initiation subsequent therapy , primary analysis cutoff date , whichever come first .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patients advance solid tumor standard alternative treatment . Availability archive tumor tissue SAR428926 target antigen test . For participant Escalation Phase : human epidermal growth factor receptor 2 ( HER2 ) negative breast cancer ( BC ) , gastric cancer , colorectal cancer ( CRC ) , ovarian cancer , prostate cancer non smallcell lung cancer ( NSCLC ) . For participant Expansion Phase : patient TNBC , prostate cancer , CRC , ovarian cancer NSCLC positive SAR428926 target antigen . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 one lesion amenable biopsy expansion cohort ( except NSCLC patient ) . Exclusion criterion : Age le 18 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status 1 . New progress brain metastasis . Concurrent treatment anticancer therapy inadequate washout period prior anticancer therapy , include experimental anticancer treatment , first administration SAR428926 , non resolution toxicity induce anticancer therapy . Women reproductive potential male subject female partner childbearing potential willing avoid pregnancy . Pregnancy breast feeding . Prior maytansinoid treatment ( DM1 DM4 antibody drug conjugate [ ADCs ] ) . Unwillingness inability comply schedule visit , drug administration plan , laboratory test , study procedure , study restriction . Significant concomitant illness , include psychiatric condition , opinion Investigator Sponsor , would adversely affect patient 's participation study . Any surgery within precede 3 week . Known human immunodeficiency virus ( HIV ) infection active hepatitis B C viral infection . Poor bone marrow reserve . Poor kidney liver function . Previous history chronic corneal disease ( even asymptomatic ) unresolved acute nonrecurrent corneal condition . Patients wear contact lens willing stop wearing duration study . Unresolved sign symptom peripheral neuropathy ; Grade 1 acceptable . Abnormal cardiac function define leave ventricular ejection fraction ( LVEF ) &lt; 50 % . Known intolerance infuse protein product include monoclonal antibody ADCs . Medical condition require concomitant administration medication narrow therapeutic window , metabolize CYPs dose reduction consider . Medical condition require concomitant administration strong CYP3A inhibitor , unless discontinue least two week first administration SAR428926 . Other prior neoplasm . Contraindications use ophthalmic vasoconstrictor and/or corticosteroid per package insert drug , include follow : increase intraocular pressure , prior current glaucoma , narrowangle glaucoma , ongoing eye infection , uncontrolled hypertension , known/suspected allergy constituent preparation ( sodium bisulfite ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>